Selection and early clinical evaluation of the brain‐penetrant 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) inhibitor UE2343 (Xanamem™)

BACKGROUND AND PURPOSE: Reducing glucocorticoid exposure in the brain via intracellular inhibition of the cortisol‐regenerating enzyme 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) has emerged as a therapeutic strategy to treat cognitive impairment in early Alzheimer's disease (AD). We sou...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Pharmacol
Päätekijät: Webster, Scott P, McBride, Andrew, Binnie, Margaret, Sooy, Karen, Seckl, Jonathan R, Andrew, Ruth, Pallin, T David, Hunt, Hazel J, Perrior, Trevor R, Ruffles, Vincent S, Ketelbey, J William, Boyd, Alan, Walker, Brian R
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2017
Aiheet:
Research Papers
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5301048/
https://ncbi.nlm.nih.gov/pubmed/28012176
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13699
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia